Leadership

Mr. Newton joined the Novavax  Board  of Directors in 2025, bringing nearly three decades of financial and executive expertise in the healthcare industry.

Mr. Newton previously served as Chief Financial Officer of Lyell Immunopharma where he led financial strategy and operations, prior to which he was at Bank of America Merrill Lynch, where he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas. Earlier in his career, he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, Managing Director and Head of Western Region Healthcare Investment Banking at Morgan Stanley and as a Corporate Finance Analyst at Lehman Brothers. 

Mr. Newton currently serves as a board member at Coherus Oncology, Inc. and previously served on the board of directors of 2seventy bio, Inc until their acquisition byBristol Myers Squibb, and Carmot Therapeutics, until their acquisition by Roche. 

Mr. Newton holds a Master of Business Administration from The Tuck School of Business at Dartmouth College and a Bachelor of Arts from Miami University.